ERCC4 and cancer: Hypersensitivity of ERCC1 and XPF mutant cells to crosslinking anti‐cancer drugs is well documented (McHugh et al, 2001); however, whether SNM1A‐deficient cells recapitulate this sensitivity is unknown.